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Abstract
Purpose of review—Rho kinases (ROCKs) are involved in regulating a variety of physiologic 
functions including cytoskeletal reorganization, migration, adhesion, survival and proliferation. 
They do so via activating several different downstream substrates such as myosin light chain 
phosphatase, LIM kinase and ezrin/radixin/moesin proteins. To date, most of the conclusions with 
regard to the function of ROCKs have involved the use of cell line models, pharmacologic 
inhibitors and dominant negative approaches. Importantly, the role of ROCK in hematopoiesis or 
leukemogenesis in the context of whole organism remains poorly understood.
Recent findings—Recent studies utilizing mice deficient in the expression of ROCK1 have 
begun to shed some light into the physiologic role(s) of ROCK in both normal and abnormal 
hematopoiesis. Findings, thus far, suggest that ROCK plays an essential role in regulating growth 
and survival in different hematopoietic lineages via distinct mechanisms, in part, by utilizing 
distinct downstream substrates including maintaining the activation of tumor-suppressor genes.
Summary—In blood cells, emerging data suggest that ROCK plays an essential role in 
negatively regulating inflammatory and erythropoietic stress and positively regulates the growth 
and survival of leukemic cells.
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INTRODUCTION
Members of the Rho guanosine 5’-triphosphatase (GTPase) family play an essential role in 
regulating cell migration, proliferation and apoptosis [1,2]. They stimulate contractility and 
adhesion by generating actin stress fibers and focal adhesions in diverse cell types [3]. Rho 
GTPases cycle between guanosine 5’-diphosphate-bound inactive and guanosine 5’-
triphosphate-bound active forms and the guanosine 5’-triphosphate-bound form binds to 
specific targets that exert biological functions [4,5]. Two closely related Rho kinases 
(ROCKs), ROCK1 and ROCK2, act as downstream effectors of Rho GTPases and 
contribute to multiple cytoskeletal functions [6,7]. Although informative, it is important to 
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recognize that most of the conclusions with regard to ROCK have been based on studies 
conducted in cells of nonhematopoietic lineages. Furthermore, while ROCK1 and ROCK2 
share significant sequence homology in the kinase domain (>90%), the regulatory domains 
at the C terminus show significant divergence [8,9]. Although the functional differences 
between ROCK1 and ROCK2 are poorly understood, pharmacologic studies as well as 
studies conducted with activated and dominant active versions of ROCK in 
nonhematopoietic cells suggest that ROCKs contribute to increased actin–myosin II-
mediated contractility by directly phosphorylating myosin light chain (MLC) and negatively 
regulating MLC phosphatase by phosphorylating the myosin-binding subunit of MLC 
phosphatase [8–12]. ROCKs also activate LIM kinase, phosphorylate cofilin and inhibit its 
actin-depolymerization activity, leading to stabilization of actin stress fibers in fibroblasts 
[13–15]. How isoform-specific forms of ROCK regulate normal and abnormal blood cell 
development and function in the context of whole organisms is only beginning to be 
unraveled. Here, we briefly summarize some recent findings related to this topic and provide 
some future perspectives.
Rho KINASES AND HUMAN EMBRYONIC STEM CELLS
Although less is known about ROCK’s role in hematopoietic stem cell (HSC) biology, 
recent studies show that pharmacologic inhibition of ROCK results in enhanced survival of 
human embryonic stem (hES) cells and enhanced survival of ROCK1 heterozygous mice in 
response to ultraviolet-induced stress compared with wild-type control mice [16,17]. 
Inhibition of ROCKs also results in reduced apoptosis of cardiomyocytes during ischemia–
reperfusion injury [18]. Similarly, pharmacologic inhibition of ROCK activity by ROCK 
inhibitor results in enhanced recovery of cryopreserved hES cells as well as induced 
pluripotent stem cells [16,19]. Furthermore, treatment with ROCK inhibitor also results in 
an increase in the colony number and size of hES cells [20]. In the context of hES cells, 
ROCK inhibitor inhibits ROCK-dependent hyperactivation of actomyosin, which is 
triggered by loss of E-cadherin-dependent intercellular contact [21]. Collectively, these 
results suggest that loss of ROCK or inhibition of ROCK activity is associated with 
enhanced survival of hES cells. Whether a similar pathway is also active in HSCs remains to 
be determined.
Rho KINASE IN MYELOID CELL BIOLOGY
Although the role of ROCK in the context of primitive HSCs remains to be investigated, 
recent findings have begun to shed some light into how ROCK regulates myeloid cell 
functions. Vemula et al. [22] investigated the role of ROCK1 in inflammatory cell migration 
including macrophages and neutrophils using ROCK1−/− mice. These authors demonstrated 
an unexpected role for ROCK1 in negatively regulating the recruitment and migration of 
primary macrophages and neutrophils in vitro and in vivo in the context of whole organism. 
Specifically, they showed enhanced migration of both macrophages and neutrophils in 
response to multiple stimuli, including macrophage colony-stimulating factor (M-CSF), 
fibronectin, monocyte chemoattractant protein-1 and formyl–methionyl–leucyl–
phenylalanine. The defects they observed were present in ROCK1−/− bone marrow-derived 
macrophages, peritoneal cavity-derived macrophages and neutrophils. Importantly, the 
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observed defects were not because of the changes in the maturation and expression of β1 
integrins or because of the changes in the expression of ROCK2 in ROCK1−/− cells. At the 
biochemical level, they showed a critical and unique role for ROCK1 in regulating the 
intracellular levels of phosphatidylinositol (3,4,5)-triphosphate/AKT in response to receptor 
activation by regulating the phosphorylation, degradation, stability and activity of tumor-
suppressor protein phosphatase and tensin homolog (PTEN). Specifically, they showed that 
the serine/threonine kinase ROCK1 binds to PTEN in response to M-CSF stimulation and 
that this binding is enhanced when PTEN is phosphorylated. Furthermore, M-CSF-induced 
ROCK1 activity induces the phosphorylation of at least serine (Ser) 380, threonine (Thr) 
382 and Thr383 in the PTEN carboxy tail. In the absence of ROCK1 expression, no physical 
association between PTEN and ROCK2 is observed. As a consequence, carboxy-terminal 
Ser380, Thr382 and Thr383 show significant impairment in phosphorylation, which results 
in enhanced degradation, reduced stability and reduced overall PTEN activity in these cells. 
The functional changes in ROCK1−/− cells take place in spite of the presence of ROCK2, 
suggesting that ROCK1 functions with specificity in regulating the phosphorylation, 
stability and activity of PTEN and in repressing the recruitment of inflammatory cells during 
infection. Vemula et al.’s [22] findings are consistent with other studies showing a critical 
role for ROCK in regulating PTEN localization using a pharmacologic inhibitor of ROCK 
[23]. These studies found PTEN to colocalize with active RhoA at the posterior of the cell. 
Thus, it appears that at least in macrophages or inflammatory cells, ROCK1 is the principal 
regulator of PTEN phosphorylation on serine and threonine residues in response to M-CSF 
and plays an important role in regulating the stability and activity of PTEN. Importantly, 
deregulation of this pathway in ROCK1-deficient cells results in enhanced recruitment of 
macrophages in vivo. Vemula et al.’s [22] results in primary ROCK1 deficient cells 
demonstrating enhanced degradation and reduced stability of PTEN due to reduced 
phosphorylation of PTEN on serine and threonine residues are consistent with previous 
studies implicating these three residues in regulating PTEN stability and degradation. Using 
serine or threonine to alanine mutants of PTEN and overexpression systems, Vazquez et al. 
[24] showed that point mutations in either serine or threonine residues render less-stable 
PTEN. Although, the precise mechanism by which the PTEN protein in ROCK1-deficient 
cells is degraded is unclear; PTEN tail contains two putative PEST sequences that have been 
implicated in targeting proteins for proteolytic degradation. One of the putative PEST 
sequence includes the three residues that show defective phosphorylation of PTEN in 
ROCK1-deficient cells (i.e. Ser380, Thr382 and Thr383), raising the possibility that PTEN 
might be targeted for proteosomal or caspase-3-mediated degradation in ROCK1 cells. 
Given the fact that PTEN plays an essential role in regulating the self-renewal of HSCs, it 
will be interesting to determine whether ROCK1 also regulates PTEN activity and 
consequently self-renewal of HSCs.
Rho KINASE IN STRESS ERYTHROPOIEISIS
Although several downstream signaling molecules have been identified that regulate steady-
state erythropoiesis, the major regulators under conditions of stress remain poorly defined. 
In this context, Vemula et al. [25▪▪] have recently shown that lack ofROCK1in a 
phenylhydrazine-induced oxidative stress model results in enhanced recovery from 
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hemolytic anemia as well as enhanced stress erythropoiesis compared with control mice. 
Deficiency of ROCK1 also results in enhanced survival, whereas wild-type mice die rapidly 
in response to stress. Enhanced survivability of ROCK1-deficient mice is associated with 
reduced level of reactive oxygen species. Bone marrow transplantation studies revealed that 
enhanced stress erythropoiesis in ROCK1-deficient mice is stem cell autonomous. 
Biochemically, ROCK1 uniquely regulates the expression of p53 in response to oxidative 
stress by regulating its phosphorylation. Interestingly, ROCK1 physically associates with 
p53 in normal splenocytes in response to oxidative stress. In the absence of this interaction, 
reduced caspase-3 cleavage and reduced level of reactive oxygen species are observed. Prior 
studies have shown that loss of p53 in p53-deficient mice also results in enhanced erythroid 
cell recovery following an oxidative challenge [26].Thus, these studies reveal a novel 
mechanism of p53 regulation in stress erythropoiesis. Given the fact that p53 levels are often 
upregulated in erythroid progenitors derived from patients with Diamond–Blackfan anemia, 
which is associated with enhanced apoptosis and reduced cell cycle, it will be interesting to 
determine whether inhibition of ROCK1 expression in these cells will rescue the survival 
and associated cell cycle defects in cells harboring mutations in the ribosomal protein 
subunit 19 [27]. Taken together, studies described in ROCK1-deficient mice, thus far, 
suggest that ROCK1 may play an essential role in negatively regulating the survival of 
multiple hematopoietic lineages in the context of both inflammatory as well as oxidative 
stress in myeloid and erythroid cells, respectively, in part by regulating the activation of 
tumor-suppressor genes such as PTEN and p53. It remains to be seen whether this is true for 
other lineages as well.
Rho KINASE IN LEUKEMOGENESIS
Although the role of ROCK in solid tumor metastasis has been well established, its role in 
the context of leukemogenesis is only beginning to be unraveled [28]. Small molecule 
inhibitors of ROCK, namely fasudil (HA-1077), Y27632 and H-1152P or dimethylfasudil, 
have been used to assess the role of ROCK in leukemogenesis [28]. These inhibitors inhibit 
the activity of both ROCK1 and ROCK2 in an ATP-competitive manner. Of the four most 
well described ROCK inhibitors, fasudil is the only one currently used in humans for the 
treatment of cardiovascular diseases such as hypertension, angina and stroke. Mali et al. [28] 
recently demonstrated constitutive activation of ROCK in leukemic cells expressing 
activating forms of KIT, FMS-like tyrosine kinase 3 and breakpoint cluster region–abelson 
kinase, which are oncogenes commonly found in patients with systemic mastocytosis, acute 
myeloid leukemia (AML) and chronic myeloid leukemia, respectively. All three oncogenes 
are associated with poor prognosis and survival in these patients. Mali et al. [28] showed 
that either loss of ROCK1 in HSCs bearing the oncogenes described above or 
pharmacologic inhibition of ROCK in leukemic cells inhibited the growth and survival of 
leukemic cells in vitro and, importantly, prolonged the lifespan of leukemic mice in vivo. 
Although Vemula et al. [25▪▪] found that in the context of stress responses ROCK1 regulates 
PTEN and p53 activation and negatively impacts stress hematopoiesis, in the context of 
leukemogenesis Mali et al. [28] found an essential role for MLC. They found MLC to be 
constitutively hyperphosphorylated on Ser19 in leukemic cells, whose activation could be 
rapidly inhibited upon treating the leukemic cells with ROCK inhibitors. Importantly, 
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increased MLC phosphorylation in leukemic cells was associated with enhanced actin 
polymerization, which was inhibited in the presence of ROCK inhibitors and associated with 
rapid F-actin depolymerization followed by membrane blebbing and rapid cell death. This 
phenomenon was somewhat unique to leukemic cells; thus, it is likely that MLC may be 
uniquely involved in the growth of leukemic cells but not normal hematopoietic cells as 
further shown by MLC knockdown experiments [28].
Although ROCK inhibitors are good initial tools to dissect the role of ROCK in leukemic 
blasts, further experiments utilizing mice deficient in the expression of ROCK1, ROCK2 
and both ROCK1 and ROCK2 will be needed to more precisely delineate the role of ROCK 
in initiation and progression of leukemia. In addition, it will be useful to assess whether the 
traditional well-characterized substrates of ROCK, such as LIM kinase and Ezrin, also 
contribute to leukemogenesis via the oncogenes described above. Small molecule inhibitors 
and mice deficient in the expression of these kinases have been described and will likely 
function as useful tools to dissect their respective role(s) in the context of leukemogenesis. 
An additional important question that remains to be answered relates to the involvement of 
ROCK1 and ROCK2 in regulating the growth and survival as well as actin-based functions 
in leukaemia-initiating cells or leukemia stem cells as well as their role in regulating drug-
resistant mutations of breakpoint cluster region–abelson kinase in chronic myeloid leukemia 
and FMS-like tyrosine kinase 3–internal tandem duplication in AML. Some studies in this 
area are already being conducted. Recent studies involving an unbiased genome-wide 
pooled short hairpin ribonucleic acid screen in primary human AML cells revealed that 
knockdown of ROCK1 in human primary leukemic blasts results in rapid cell cycle arrest 
and cell death. Treatment with fasudil proved to be equally effective in killing leukemic 
cells in these studies. Importantly, fasudil was less toxic to normal hematopoietic cells 
compared to primary leukemic cells. Fasudil treatment of these cells suggested that it had a 
significant negative effect on the self-renewal capacity of primary human leukemic stem/
progenitor cells [29▪].
Once a better understanding of the individual role(s) of ROCK isoforms in normal 
hematopoiesis and in leukemogenesis is established, the development of isoform-specific 
ROCK inhibitors may be a worthwhile strategy, in light of the fact that some patients with 
benign hematologic issues such as Diamond–Blackfan anemia may respond better to 
ROCK1 inhibitors versus patients with malignant hematologic diseases that may respond 
better to ROCK1 and/or ROCK2 inhibitors.
CONCLUSION
Although several substrates of ROCK have been identified in cells of nonhematopoietic 
lineages, few have been identified in primary hematopoietic cells. ROCK isoforms are likely 
to regulate functions in different cell types via distinct and in some cases perhaps 
overlapping substrates. It is, therefore, important to assess the role of ROCK isoforms in the 
context of a specific cell type and in primary cells. Likewise, it would be interesting to 
determine whether the classical ROCK substrates, such as LIM kinase and/or Ezrin’s loss of 
function in specific hematopoietic lineages, will result in similar functional defects as 
ROCK1 and/or ROCK2-deficient cells. An additional key question is to determine which 
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ROCK substrates are critical for normal hematopoietic function and which are relevant for 
leukemogenesis. More importantly, can this information be used to differentially target 
molecules in leukemogenesis versus normal hematopoietic functions? A better 
understanding of the biology of these kinases and their substrates is likely to result in better 
strategies for targeting these related yet distinct molecules in different hematologic diseases.
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• ROCK1 negatively regulates stress hematopoiesis, in part, by regulating the 
activation of tumor-suppressor genes such as PTEN and p53.
• ROCK is constitutively activated in leukemic cells and its inhibition results in 
cell death of leukemic cells partly via regulating the activation of MLC.
• ROCK regulates cellular functions in various hematopoietic lineages via distinct 
mechanisms.
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